Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.

CONTEXT GH replacement therapy (GH-RT) is a widely accepted treatment in GH-deficient adults with nonfunctioning pituitary adenoma (NFPAs). However, some concerns have been raised about the safety of GH-RT because of its potentially stimulating effect on tumor growth. OBJECTIVE The aim of this study was to evaluate tumor progression in NFPA patients using GH-RT. DESIGN, SETTING, AND PATIENTS From the Dutch National Registry of Growth Hormone Treatment in Adults, a nationwide surveillance study in severely GH-deficient adults (1998-2009), all NFPA patients with ≥ 30 days of GH-RT were selected (n = 783). Data were retrospectively collected from the start of GH-RT in adulthood (baseline). MAIN OUTCOME MEASURE Tumor progression, including tumor recurrence after complete remission at baseline and regrowth of residual tumor. RESULTS Tumor progression developed in 12.1% of the patients after a median (range) time of 2.2 (0.1-14.9) years. Prior radiotherapy decreased tumor progression risk compared to no radiotherapy (hazard ratio = 0.16; 95% confidence interval, 0.09-0.26). Analysis in 577 patients with available baseline imaging data showed that residual tumor at baseline increased tumor progression risk compared to no residual tumor (hazard ratio = 4.5; 95% confidence interval, 2.4-8.2). CONCLUSIONS The findings in this large study were in line with those reported in literature and provide further evidence that GH-RT does not appear to increase tumor progression risk in NFPA patients. Although only long-term randomized controlled trials will be able to draw firm conclusions, our data support the current view that GH-RT is safe in NFPA patients.

[1]  D. Leroith,et al.  Growth hormone treatment induces mammary gland hyperplasia in aging primates , 1997, Nature Medicine.

[2]  D. Russell-Jones,et al.  Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? , 2002, European journal of endocrinology.

[3]  N. Karavitaki,et al.  GH replacement in patients with non‐functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence , 2009, Clinical endocrinology.

[4]  J. Hardy,et al.  The clinical and endocrine outcome to trans‐sphenoidal microsurgery of nonsecreting pituitary adenomas , 1991, Cancer.

[5]  J. Koivukangas,et al.  Incidence of pituitary adenomas in Northern Finland in 1992-2007. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  M. Heymans,et al.  Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. , 2011, The Journal of clinical endocrinology and metabolism.

[7]  S. Ashley,et al.  The incidence of cerebrovascular accidents in patients with pituitary adenoma. , 1999, International journal of radiation oncology, biology, physics.

[8]  L. Behan,et al.  The natural history of surgically treated but radiotherapy‐naïve nonfunctioning pituitary adenomas , 2009, Clinical endocrinology.

[9]  D Uttley,et al.  The long‐term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas , 1993, Clinical endocrinology.

[10]  S. Ashley,et al.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. , 2005, The Journal of clinical endocrinology and metabolism.

[11]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[12]  J. Twisk,et al.  Dutch National Registry of GH Treatment in Adults: patient characteristics and diagnostic test procedures. , 2011, European journal of endocrinology.

[13]  R. Clayton,et al.  Radiotherapy for non-function pituitary tumours. , 1998, Clinical endocrinology.

[14]  T. Spinks,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients , 2022 .

[15]  Bates,et al.  Radiotherapy for non‐functioning pituitary tumours , 1998 .

[16]  B. Bengtsson,et al.  GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety , 1999, Clinical endocrinology.

[17]  Stratton,et al.  Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation — a follow‐up study , 1999, Clinical endocrinology.

[18]  H. Shih,et al.  Radiation therapy in the management of pituitary adenomas. , 2011, The Journal of clinical endocrinology and metabolism.

[19]  Brenda J. Crowe,et al.  Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients , 2013, The Journal of clinical endocrinology and metabolism.

[20]  O. Gudmundsen,et al.  Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. , 2011, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[21]  O. Dekkers,et al.  Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  B. Wolffenbuttel,et al.  Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. , 2007, International journal of radiation oncology, biology, physics.

[23]  G. Brabant,et al.  Long-term safety of growth hormone replacement after CNS irradiation. , 2011, The Journal of clinical endocrinology and metabolism.

[24]  G. Brabant,et al.  Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. , 2007, European journal of endocrinology.

[25]  S. Grottoli,et al.  Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[26]  W. Shi,et al.  Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  E. Ghigo,et al.  Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  M. Vance,et al.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. , 2006, The Journal of clinical endocrinology and metabolism.

[29]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[30]  H. de Boer,et al.  Clinical aspects of growth hormone deficiency in adults. , 1995, Endocrine reviews.

[31]  R. Tsang,et al.  Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk , 1993, Cancer.

[32]  W. Drake,et al.  Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. , 2001, The Journal of clinical endocrinology and metabolism.

[33]  J. Ket,et al.  Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity , 2014, Clinical endocrinology.

[34]  M. Preece,et al.  Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study , 2002, The Lancet.

[35]  M. Ranke,et al.  Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). , 2010, The Journal of clinical endocrinology and metabolism.

[36]  M. Buchfelder,et al.  Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. , 2009, European journal of endocrinology.

[37]  W. Drake,et al.  Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. , 2010, European journal of endocrinology.

[38]  M. Drent,et al.  Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults. , 2015, The Journal of clinical endocrinology and metabolism.

[39]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.